Navigation Links
Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation
Date:2/7/2013

5 million people globally suffer from Parkinson's disease, a neurodegenerative disorder caused by the diminished production of dopamine, a key neurotransmitter, resulting in progressive impairment of motor function including tremors, rigidity and difficulty in moving. Long-term treatment of Parkinson's disease (PD) patients with levodopa, also called L-dopa, typically leads to unwanted side effects including L-dopa induced dyskinesia (LID), which prevents optimal treatment of the disease.

L-dopa Induced Dyskinesia
Levodopa, also called L-dopa, is the most commonly administered drug to treat Parkinson's symptoms. L-dopa helps restore levels of dopamine, a chemical messenger in the brain responsible for smooth, coordinated movement and other motor and cognitive functions. Dyskinesia is a common side effect of L-dopa treatment. These involuntary, uncontrollable, and often excessive movements are distinct from the rhythmic tremor commonly associated with Parkinson's disease.

About Metabolic Solutions Development Company
Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially type 2 diabetes.

About The Michael J. Fox Foundation for Parkinson's Research
As the world's largest private funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $313 million in research to date, the Foundation has fundamenta
'/>"/>

SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Metabolic Solutions Development Company announces publication of Phase 2b data in Clinical Pharmacology & Therapeutics
2. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
3. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
4. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
5. New Wellness Products with Results that Identify Healthiness, Deficiencies and Solutions
6. H. D. Smith Specialty Solutions Appoints 20-year Industry Veteran Tim Booth To Executive Vice President, Smith Medical Partners
7. BioLife Solutions Appoints Rick Stewart To Board of Directors
8. New Findings Offer Systemic Solutions to Address Non-communicable Diseases (NCDs) in Low- and Middle-income Countries
9. Omnicell to Showcase Automation Solutions at Arab Health 2013
10. Elekta to Showcase Broad Portfolio of Cancer Management Solutions at 2013 Arab Health Congress and Exhibition
11. H. D. Smith Establishes Specialty Solutions Organization And Realigns Senior Leadership To Support Growing Geographic Reach, Diversified Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014  AnaptysBio, Inc., a leader ... today announced the appointment of Marco Londei ... will lead the preclinical and clinical development of ... are pleased to welcome Dr. Londei to AnaptysBio,s ... President and Chief Executive Officer of AnaptysBio. "Dr. ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, received official notification from ... been granted another key patent supporting its iSONEP™ ... issued patent, European patent No. 2087002, claims compositions ... in Lpath,s two lead compounds, iSONEP and ASONEP. ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... for Caring, is a 4-Star Sponsor of Operation ... Veterans with unique products, programs and services to assist ... freedom. Key Facts: , An ... is a safe and effective treatment for pain, Post-traumatic ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3
... and MONTREAL, Aug. 21 Pharmion,Corporation (Nasdaq: ... MYG), today announced that the U.S. Food and ... (HDAC) inhibitor,MGCD0103, as an Orphan Drug for the ... for designation require that the product be,intended for ...
... Aug. 21 Advanced Life Sciences,Holdings, Inc. ... commencement of its,collaboration with the National Institute ... governmental institute supporting biodefense,research, under which the ... Company,s late-stage antibiotic, as a treatment for,anthrax ...
Cached Medicine Technology:Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma 2Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma 3Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma 4Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... National Teen Driver Safety Week is October ... of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the ... teen drivers to talk to their teens and always set ... crashes are the leading cause of death for U.S. teens. ... crashes, and 859 (42%) of those teen drivers were killed ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 Houston ... to present the key elements of his innovative ... professor to plastic surgery residents and faculty at ... , where he, too, was once a medical student. ... the largest private cosmetic plastic surgery practices in Texas, ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... 2014 SweetDressy.com, a professional company of ... promotion for long evening dresses . All the ... offer; the current discount is up to 66 percent ... pioneers in the fashion field. Its dress specialists are ... in various parts of the world. All the company’s ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay News) ... only protect themselves throughout their pregnancy but may also help ... of life. A study published online Oct. 4 ... found that when women were vaccinated in the second or ...
... that sucks up dangerous plaque debris could trigger a "paradigm ... in the current issue of Endovascular Today . ... write Dr. Robert Dieter of Loyola University Health System and ... clinical trials totaling 123 patients, the device had a success ...
... Scott & White Cancer Center,s Breast Cancer Clinic program ... National Accreditation Program for Breast Centers (NAPBC), a program ... Scott & White breast cancer is managed by a ... in excellent care," said Christopher O. Ruud, M.D., director ...
... Madonna Behen HealthDay Reporter , TUESDAY, Oct. ... help doctors one day identify which patients with mild ... Swiss researchers report. Using a combination of specialized ... University Hospitals of Geneva said they were able to ...
... be an efficient alternative when common drugs do not ... animals such as mice could not be used: The ... them. In an international cooperation, scientists from the Helmholtz ... now succeeded in developing a promising approach to solve ...
... most toxic free radical appears responsible for much of ... in the critically ill or injured, Medical College of ... and oxygen chambers used to significantly increase oxygen levels ... powerful enough to break down DNA and cause proteins ...
Cached Medicine News:Health News:Mom's Flu Shot May Protect Baby After Birth 2Health News:Mom's Flu Shot May Protect Baby After Birth 3Health News:'Paradigm shift' in how physicians treat peripheral artery disease 2Health News:Scott & White breast cancer program receives accreditation 2Health News:Computer-Aided MRI Might Help Predict Alzheimer's 2Health News:Computer-Aided MRI Might Help Predict Alzheimer's 3Health News:Mice with human body's defenses 2Health News:Powerful free radical causes lung damage from oxygen therapy 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: